$CMMB News
Last published 3d ago
- 3d agoCMMBChemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireChemomab Therapeutics announced financial and operating results for the third quarter of 2026 and provided a corporate update.
- 2w agoCMMBChemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is EffectiveGlobeNewswireSpecial meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (NASDAQ:CMMB)
- 2mo agoCMMBChemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor ConferenceGlobeNewswireTEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high
- 3mo agoCMMBChemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireProposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with
- 4mo agoCMMBChemomab Therapeutics and Scipher Medicine Merger Announcement Conference Call - Chemomab TherapeuticsEarnings Call TranscriptsGreetings and welcome to the Chemomab Therapeutics and Cypher Medicine Merger Announcement Conference Call. At this time, all participants are on a listen-only mode. As a reminder, this conference is being recorded. It i
- 4mo agoCMMBChemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisGlobeNewswireCombined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to
- 6mo agoCMMBChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC
- 9mo agoCMMBChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireTEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 11mo agoCMMBChemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of GastroenterologyGlobeNewswire—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL AVIV, Israel, Dec. 02,
- 12mo agoCMMBChemomab to Participate in Oppenheimer's Movers in Rare Disease SummitGlobeNewswireTEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 1y agoCMMBChemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite
- 1y agoCMMBChemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing CholangitisGlobeNewswire— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on
- 1y agoCMMBChemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireTEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 1y agoCMMBChemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique Anti-Fibrotic,
- 1y agoCMMBChemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25GlobeNewswireSPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and
- 1y agoCMMBChemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing CholangitisGlobeNewswire—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners
- 1y agoCMMBChemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing CholangitisGlobeNewswire—New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041— —Further Expands Protections Provided by
- 1y agoCMMBChemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire—Reported Positive 48-Week Data from SPRING Trial—Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis—
- 1y agoCMMBChemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025GlobeNewswireSPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory
- 1y agoCMMBChemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related DiseasesGlobeNewswireNew Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the
- 1y agoCMMBChemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific ConferencesGlobeNewswireTEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet
- 1y agoCMMBChemomab Announces New Medical and Clinical AppointmentsGlobeNewswireDavid M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the
- 1y agoCMMBChemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver BiomarkersGlobeNewswireReinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced
- 1y agoCMMBNew Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic SclerosisGlobeNewswireAdds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd.
- 1y agoCMMBChemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswire─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to
- 1y agoCMMBChemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing CholangitisGlobeNewswireSingle Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC
- 1y agoCMMBChemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireTEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 1y agoCMMBChemomab to Participate in Oppenheimer's Movers in Rare Disease SummitGlobeNewswire—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companieswith "Key, Near-Term, Potentially Stock-Moving Catalysts"— TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Chemomab
- 2y agoCMMBOral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing CholangitisGlobeNewswire—Clinical Data from Phase 2 SPRING Trial Shows that CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis— TEL AVIV, Israel, Nov.
- 2y agoCMMBChemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire──FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated Approval Phase 3 Trial in Primary Sclerosing Cholangitis (PSC)── ──Cash Runway Extended to Early 2026;
- 2y agoCMMBChemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business UpdateGlobeNewswireTEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for
- 2y agoCMMBChemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024GlobeNewswireTEL AVIV, Israel, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Therapeutics to Present at October 2024 Investor ConferencesGlobeNewswireTEL AVIV, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Therapeutics to Present at September 2024 Investor ConferencesGlobeNewswireTEL AVIV, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes Clinical
- 2y agoCMMBChemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business UpdateGlobeNewswireTEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for
- 2y agoCMMBChemomab Therapeutics Announces Closing of $10 Million Private PlacementGlobeNewswire— HBM Healthcare Investments, OrbiMed and Sphera Biotech Master Fund LP Participated in the Financing that Extends Cash Runway Potentially to the Beginning of 2026— —Chemomab is Well-Positioned to Achieve Key Clinical
- 2y agoCMMBChemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementGlobeNewswireTEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Therapeutics Announces $10 Million Private PlacementGlobeNewswireTEL AVIV, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for
- 2y agoCMMBChemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing CholangitisGlobeNewswireFirst-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across
- 2y agoCMMBChemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisGlobeNewswire—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab's CCL24-Neutralizing Antibody
- 2y agoCMMBChemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research ConferenceGlobeNewswire—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —New Translational
- 2y agoCMMBChemomab Therapeutics to Participate in Upcoming Scientific ConferencesGlobeNewswireTEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months
- 2y agoCMMBChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleGlobeNewswireTEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceGlobeNewswireTEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateGlobeNewswireTEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
- 2y agoCMMBChemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisGlobeNewswire—Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular
- 2y agoCMMBChemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024GlobeNewswire—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
- 2y agoCMMBChemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisGlobeNewswire—European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis— —Further Extends Protections Afforded by CM-101 Composition of